Semaglutide Online

SUSTAIN-6, a cardiovascular outcomes trial, showed a 26% reduction in major adverse cardiac events, including stroke and myocardial infarction. Semaglutide was designed to mimic GLP-1, but with a longer half-life and enhanced receptor binding. This allows it to be effective with once-weekly dosing, compared to earlier GLP-1 drugs that required daily injections. Semaglutide is a […]